Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163627 | 0.82 | EGFR (0.48) | EGFRKDRALDH1A1KDM4EHPGD | |
| SCHEMBL11086468 | 0.79 | EGFR (0.58) | EGFRKDRHTTALDH1A1KDM4E | |
| SCHEMBL3522576 | 0.73 | MAP2K4 (0.49) | EGFRKDRALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL12478493 | 0.71 | NPC1 (0.50) | HTTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL6168673 | 0.71 | HTT (0.53) | HTTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4230732 | 0.71 | HTT (0.53) | EGFRKDRHTTSRCLMNA | |
| SCHEMBL5562603 | 0.71 | SRC (0.42) | EGFRKDRALDH1A1KDM4EHPGD | |
| SCHEMBL10015393 | 0.70 | HTT (0.49) | HTTALDH1A1KDM4E | |
| SCHEMBL4913124 | 0.69 | ALDH1A1 (0.54) | EGFRKDRHTTALDH1A1KDM4E | |
| SCHEMBL10759577 | 0.69 | HTT (0.37) | EGFRKDRHTTSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2924037-A1 | QUINAZOLINE DERIVATE AND USE THEREOF AS APOPTOSIS INHIBITOR | Linx Pharmaceutical Co., Ltd. (CN) | 2015-09-30 | — | — | EP | disclosed |
| EP-2785699-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013079494-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-7855194-B2 | Pyrimidine, quinazoline, pteridine and triazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-21 | — | — | US | disclosed |
| EP-2001867-B1 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2001867-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110340-A2 | PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-09-27 | — | — | US | disclosed |
| US-4309541-A | CHEMICAL INTERMEDIATES TO QUINAZOLINE HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-01-05 | — | — | US | disclosed |
| US-4255429-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| EP-0009465-A1 | N-(1-(4-amino-2-quinazolinyl)-3 or 4-piperidyl lactames, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225271-A1 | Pyrimidine, quinazoline, pteridine and triazine derivatives | SSTR5, SSTR3, SSTR1 | EGFR 857/4885KDR 320/4885HTT 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.